Latest news

IO Biotech eyes FDA nod for skin cancer vaccine despite narrow trial miss

IO Biotech eyes FDA nod for skin cancer vaccine despite narrow trial miss

Joachim Eeckhout
Novartis scores a Phase 3 win in Sjögren’s syndrome, salvaging value from its $2.9B MorphoSys buy

Novartis scores a Phase 3 win in Sjögren’s syndrome, salvaging value from its $2.9B MorphoSys buy

Joachim Eeckhout
Daily Snap - 11. August 2025

Daily Snap - 11. August 2025

Joachim Eeckhout
Gilead axes 3 drug programs, including Novo-partnered MASH treatment

Gilead axes 3 drug programs, including Novo-partnered MASH treatment

Joachim Eeckhout
BioNTech settles $870M patent dispute with CureVac, clearing path for $1.25B buyout

BioNTech settles $870M patent dispute with CureVac, clearing path for $1.25B buyout

Joachim Eeckhout
Daily Snap - 8. August 2025

Daily Snap - 8. August 2025

Joachim Eeckhout
XtalPi and DoveTree launch $6B AI-powered push to “drug the undruggable”

XtalPi and DoveTree launch $6B AI-powered push to “drug the undruggable”

Joachim Eeckhout
Strand Therapeutics lands $153M to push forward “programmable” mRNA cancer drugs

Strand Therapeutics lands $153M to push forward “programmable” mRNA cancer drugs

Joachim Eeckhout
OpenAI-backed Chai raises $70M to fast-track AI-driven drug discovery

OpenAI-backed Chai raises $70M to fast-track AI-driven drug discovery

Joachim Eeckhout
Nxera doubles down on obesity drugs as Pfizer, Novo and Terns exit GLP-1 candidates

Nxera doubles down on obesity drugs as Pfizer, Novo and Terns exit GLP-1 candidates

Joachim Eeckhout
Daily Snap - 6. August 2025

Daily Snap - 6. August 2025

Joachim Eeckhout
SERB buys Y-mAbs for $412M to expand rare cancer pipeline

SERB buys Y-mAbs for $412M to expand rare cancer pipeline

Joachim Eeckhout
FirstBack
2324252627282930
Next Last